Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07333261 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 1
SponsorSusan Bal
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Eligibility criteria expanded, about 9 words · Secondary endpoints: details revised at 1 of 10 entries · Site details revised Show 3 more changesShow less
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 1 of 10 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jan 2028 to Dec 2031 · Completion date: Jan 2043 to Dec 2041 · Start date changed from estimate of Jan 2026 to Feb 9, 2026 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Jan 2028 to Dec 2031
    • Completion date: Jan 2043 to Dec 2041
    • Start date changed from estimate of Jan 2026 to Feb 9, 2026
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
Trial Details
NCT Number NCT07333261
Lead Sponsor Susan Bal
Collaborators: Bristol-Myers Squibb
Conditions Multiple Myeloma
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov